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Abstract 
Considerable attention has been focused on the development of phosphonate-containing 
drugs for application in many therapeutic areas. However phosphonate diacids are deprotonated 
at physiological pH and thus phosphonate-containing drugs are not ideal for oral administration, 
an extremely desirable requisite for the treatment of chronic diseases. To overcome this 
limitation several prodrug structures of biologically active phosphonate analogues have been 
developed. The rationale behind the design of such agents is to achieve temporary blockade of 
the free phosphonic functional group until their systemic absorption and delivery, allowing the 
release of the active drug only once at the target. In this paper, an overview of acyclic and cyclic 
nucleoside phosphonate prodrugs designed as antiviral agents is presented. 
Introduction to acyclic and cyclic nucleoside phosphonate prodrugs 
Nucleoside analogues are synthetic compounds that are structurally similar to natural 
nucleosides, the building blocks of RNA and DNA. Once inside the cell, nucleoside analogues 
undergo (often three sequential) phosphorylation steps by viral and cellular kinases to generate 
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most often QXFOHRVLGHƍ-triphosphates that can act as competitive inhibitors of viral and cellular 
DNA or RNA polymerases or alternatively can be incorporated into a growing DNA or RNA 
strands, causing chain termination [1]. However, many nucleoside analogues are not 
phosphorylated effectively in vivo, in particular the first phosphorylation step is often inefficient 
and rate-limiting step in the conversion to the ¶ WULSKRVSKDWH. To circumvent this limitation, 
nucleotides with a phosphate group already attached to the nucleoside have been designed.  
However, these nucleotides become potential substrates for phosphatases, leading to removal of 
the phosphate group. Replacement of the phosphate moiety with an isosteric and isoelectronic 
phosphonate group, results in a nucleoside phosphonate; chemically and enzymatically much 
more stable than the corresponding phosphate. Different to the O-P linkage, the CH2-P-bond, due 
to its chemical nature, is not susceptible to phosphodiesterase and phosphatase hydrolysis. 
Enzymatically and chemically stable phosphonate analogues, which mimic the nucleoside 
monophosphates, can bypass the initial enzymatic phosphorylation and can potentially be more 
effective antiviral agents. Like a nucleoside monophosphate, a nucleoside phosphonate can be 
further phosphorylated by cellular nucleotide kinases. The nucleoside phosphonates are 
classified into major groups: acyclic (ANPs) and cyclic (CNPs) nucleoside phosphonates [2]. 
ANPs, originally developed by the Holý group in the 1980¶s, exhibit a broad spectrum of 
antiviral activities, particularly against DNA viruses and retroviruses [3, 4]. The common 
structural attribute of ANPs is a nucleobase attached to an aliphatic side chain containing a 
phosphonomethyl residue. A methylene bridge between the phosphonate moiety and the rest of 
the molecule excludes the possibility of enzymatic dephosphorylation. The absence of a 
glycosidic bond in the structure of ANPs further increases their resistance to chemical and 
biological degradation. Flexibility in the acyclic chain is assumed to allow these compounds, 
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once diphosphorylated, to adopt a conformation appropriate for interaction with active sites of 
different target enzymes involved in the biosynthesis of DNA (DNA polymerase for DNA 
viruses, reverse trascriptase for retroviruses). The diphosphorylated ANPs act as chain 
terminators of the viral DNA inhibiting viral replication. After the description of the first 
member of ANPs, (S)-9-(3hydroxy-2-phosphonyl-methoxypropyl)adenine ((S)-HPMPA, 1) in 
1986 [5], new generations of ANPs were prepared and evaluated for their antiviral activity [6]. 
The ANPs can be classified, according to their structure, in three different series: 3-hydroxy-2-
(phosphonomethoxypropyl) (HPMP), 2-(phosphonomethoxypropyl) (Figure 1) (PME) and 2-
(phosphonomethoxypropyl) (PMP) series (Figure 2). The HPMP series, characterized by the 
presence of a hydroxymethyl chain, exhibit (generally as the (S)-enantiomer) an antiviral activity 
against a wide spectrum of DNA viruses encompassing, in particular, adeno-, pox-, polioma-, 
papilloma- and herpesvirus infections. Among this series, derivatives of adenine (1, (S)-
HPMPA,), cytosine (3, (S)-HPMPC, Cidofovir, Vistide®, used to treat human cytomegalovirus 
(HCMV) retinitis in acquired immunodeficiency syndrome (AIDS)) [7], 2,6-diaminopurine (5, 
(S)-HPMP-DAP), 2,4-diamino-3-hydroxy pyrimidine (6, (R)-HPMPO-DAPy) and 5-azacytosine 
(7, (S)-HPMP-5-aza-C) were found to be especially potent. In particular, the DAP (2,6-
diaminopurine) derivatives show an antiviral potency and activity spectrum comparable to that of 
their adenine counterparts [8].  Thus, (S)-HPMP-DAP (3) is equivalent to (S)-HPMPA (1), i.e. 
with regard to their activity against poxviruses such as vaccinia [9] and orf virus [10]. Akin to 
(S)-HPMPA (1) and (S)-HPMPC (2), (R)-HPMPO-DAPy (4) proved to be a potent and selective 
inhibitor of adenovirus replication in vitro [11] and exhibited selective and potent activity against 
orf virus in both human and ovine cell monolayers and organotypic ovine raft cultures [10]. In 
vivo, (R)-HPMPO-DAPy (4), similarly to (S)-HPMPC (2) was shown to lead to healing of 
4 
 
cutaneous vaccinia lesions in athymic-nude mice (which corresponds to an experimental model 
infection for disseminated vaccinia in immunosuppressed patients inadvertently vaccinated with 
live smallpox vaccine) [9]. The antiviral activity of (S)-HPMP-5-aza-C (7) was also shown to be 
comparable to that of the reference drug (S)-HPMPC (3) against herpes viruses (HSV-1, HSV-2) 
and vaccinia virus (VV), or 2-7-fold more active against varicella zoster virus (VZV), HCMV, 
human herpes virus type-6 (HHV-6), and adenovirus type-2 (Ad2). For all these DNA viruses, 
(S)-HPMP-5-aza-C (7) showed a 2-16-fold higher antiviral selectivity index (ratio of CC50 to 
EC50) than (S)-HPMPC (3) [12]. In an effort to increase the cell permeability of HPMP-based 
nucleoside investigators have also generate a cyclic version of ANPs, forming an internal 
phosphonate ester bond with the hydroxymethyl chain (Figure 1). As a representative example, 
cyclic (S)-HPMPC (4) has been shown to have some advantages respect to (S)-HPMPC such as 
reduced nephrotoxicity due to diminished uptake in the renal proximal tubular cells [13]. 
Researchers have identified a cellular cCMP phosphodiesterase that can converts cHPMPC to 
(S)-HPMPC in vivo [14]. 
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Figure 1. Structures of acyclic nucleoside phosphonate HPMP and cyclic HPMP series. 
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The PME and PMP series of ANPs, which lack respectively the hydroxymethyl and 
hydroxyl groups in their acyclic side chain, are based on PMEA (8) and (R)-PMPA (9) 
structures. The PME structures unlike the HPMP and PMP series do not contain a chiral carbon 
center and thus do not exist as (R) and (S) enantiomers. The PMP series exerts its antiviral 
activity mostly as the (R)-enantiomer. These nucleotides and their analogues have shown potent 
activity against retro- and hepadnaviruses. PME-DAP (11) was found to be more active as an 
anti-retrovirus agent than PMEA (8), but also more toxic, so that its therapeutic index, based on 
its in vivo activity against murine sarcoma virus (MSV), was equivalent to that of PMEA (8) 
[15]. It was reported with even higher anti-retrovirus potency than (R)-PMPA (9) and has proved 
active against (both wild-type and lamivudine resistant) hepatitis B virus (HBV) with a potency 
comparable to that of (R)-PMPA (9) [16, 17]. ³O-OLQNHG´ $13V VXFK DV -diamino-6-[2-
(phosphonomethoxy)ethoxy]pyrimidine (12, PMEO-DAPy) and 2,4-diamino-6-(R)-[2-
(phosphonomethoxy)propoxy]-pyrimidine (13, (R)-PMPO-DAPy) were found to inhibit the 
replication of herpesviruses (HSV-1, HSV-2, VZV) as well as retroviruses such as human 
imunodeficency viruses type 1 and 2 (HIV-1, HIV-2) [18]. In particular, the antiretroviral 
activity of PMEO-DAPy (12) and (R)-PMPO-DAPy (13) appeared interesting, as this was 
comparable to that of PMEA (8) and (R)-PMPA (9) and was also observed in vivo [19]. 
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Figure 2. Structures of acyclic nucleoside phosphonate PME and PMP series. 
CNPs are real nucleoside analogues as they contain a nucleobase and a sugar moiety. 
Compared to the large number of the ANPs described in the literature, only few examples of 
CNPs endowed with antiviral activity have been reported (Figure 3) [2]. The lack of antiviral 
activity of CNPs is generally explained by their poor substrate properties for cellular and viral 
kinases. On the other hand, the potent antiviral activity of ANPs is ascribed to their intracellular 
phosphorylation to their diphosphates and to a refractory incorporation of the modified 
nucleosides in nucleic acids. To try to overcome the drawback of CNPs, compounds where the 
phosphonoalkoxy group of the nucleoside phosphonates is bound at WKH ¶-position were 
designed. Interesting examples of this class of drugs are the (L)-2-deoxythreosyl phosphonate 
nucleosides PMDTT (14) and PMDTA (15), reported as selective anti-HIV agents [20]. The 
absence of a hydroxymethyl substituent in the 4¶-position of the nucleoside can probably avoid 
OH hindrance during enzymatic phosphorylation allowing the formation of the diphosphate 
species. 
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In an effort to identify new nucleoside inhibitors of reverse trascriptase, phosphonometoxy 
analogs of cyclic pyrimidine nucleoside were synthesized and compared for their antiviral 
activity [21]. Among them, only d4TP (16) showed an antiviral activity below 200 PM. This 
approach have been recently extended to purine analogs leading to the discovery of the 
phosphonomethoxy-¶-fluoro-¶¶-dideoxy-¶¶-didehydroadenosine (17, GS-9148), a ribose-
PRGL¿HG HIV-1 nucleotide reverse transcriptase inhibitor (NRTI) selected from a series of 
nucleoside phosphonate analogues for its low mitocondrial toxicity, minimal cytotoxicity in renal 
proximal tubule cells and other cell types, for its synergy in combination with other antiretroviral 
drugs and its unique resistance SUR¿OH against multiple resistant HIV-1 strains [22]. 
O N
N
O
O
OP
O
HO
OH
O N
OP
O
HO
OH
N
N
N
NH2
O N
N
N
N
NH2
F
OP
OHO
HO
2'F-d4AP   17
GS-9148
PMDTA    14 PMDTT   15
O NO
P
OHO
HO
NH
O
O
d4TP     16
 
Figure 3. Structures of cyclic nucleoside phosphonates PMDTA (14), PMDTT (15), d4TP 
(16DQG¶)-d4AP (GS-9148, 17). 
Natural nucleosides are as well hydrophilic molecules and do not rapidly penetrate cell 
membranes by non-facilitated diffusion. Instead they permeate the cell by carrier-mediated 
endocytosis, which is an active or facilitated transport mechanism that requires energy and a 
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specific receptor or protein on the cell surface. Acyclic and cyclic nucleoside phosphonate 
analogues contain a phosphonic acid group completely ionized at physiological pH, resulting in a 
molecule largely impermeable to mucosal and cellular membranes. However carrier-mediated 
transport often requires very close structural resemblance to natural products. Because their low 
oral bioavailability ANP and CNP analogues are of limited value in the treatment of chronic 
diseases, where the oral therapies are highly desired. 
Prodrugs are used in general to bypass physicochemical, pharmaceutical, pharmacokinetic 
and pharmacodynamic barriers to drug formulation and delivery, such as poor aqueous solubility, 
chemical instability, insufficient oral absorption, rapid presystemic metabolism and inadequate 
tissue penetration. In an attempt to overcome, the limited oral bioavailability of ANPs and CPs 
ionizable phosphonate can be masked by derivatization, thus generating a prodrug with increased 
liphophilicity, capable to alter cell and tissue distribution/elimination patterns of the parent drug 
[23]. 
Passive transcellular absorption is the most general route for absorption of lipophilic 
(pro)drugs through the intestinal mucosal membranes. After the drug molecule is dissolved in the 
aqueous media, absorption occurs by diffusion through the lipid bilayer and because it is driven 
by a concentration gradient, energy is not required. Absorption is thus dependent on the 
lipophilicity, intrinsic aqueous solubility and molecular weight of the drug molecule. Once the 
drug has reached the blood circulation it will pass through the endothelium of the capillary and 
distribute into tissues. Thus also the distribution is dependent on several structural and 
physicochemical properties including the molecular size, logP, hydrogen-bonding, charge state 
and finally on its ability to be a substrate for influx and efflux transporters and to bind plasma 
proteins. The liver is the major organ for drug metabolism, but metabolism occurs also in the GI-
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tract and to some extent in lungs, skin and kidneys. First-pass metabolism consisting of phase I 
oxidation reactions catalyzed by cytochrome P450-enzymes and phase II conjugation reactions 
catalyzed by several enzymes occur in the liver. Excretion, elimination or clearance of a drug 
molecule from the body starts immediately after the drug has entered the circulation and two 
organs are mainly responsible for it: the liver and the kidney. Renal clearance occurs via 
filtration of the blood in the glomerulus of the kidneys and the further reabsorption of the 
compounds from the kidney tubule back to the systemic circulation with the molecular weight 
and liphophilicity of the drug molecule playing a key role in these events.   
 In order to achieve oral bioavailability and intracellular delivery an ideal oral prodrug must 
survive the gastrointestinal (GI) tract, be absorbed across intestinal mucosa and delivered into the 
systemic circulation following its active/passive transport, and then be distributed into cells 
where it has to be converted to the parent drug releasing a non-toxic promoiety, which in turn has 
to be rapidly excreted from the body. Thus, stability is one of the major factors influencing the 
design of prodrugs. The bioactivation mechanism for most prodrug structures is enzymatic or at 
least requires enzymes to initialize the bioactivation process, which can then further continue 
chemically. 
Several prodrug approaches have been utilized to overcome the limitation of phosphonate-
containing drugs. General reviews about prodrug strategies elaborated for phosphate-, 
phosphonate- and phosphinates-containing compounds [24-27] and more specific reviews 
directed toward delivery of nucleoside and nucleotide have been published [23, 28-30]. The aim 
of this review is to survey specifically the status and the recent progress in the design and 
development of acyclic and cyclic nucleoside phosphonate prodrugs, focusing on the most 
promising strategies currently under development in the antiviral area.  
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Bis-(POM) and bis-(POC) esters prodrugs 
The development of acyloxy ester alkoxycarbonyl ester prodrugs of ANPs has been 
successful. Among these ester prodrugs two compounds are currently marketed for antiviral 
therapy: the bis (pivaloyloxymethyl) ester of adefovir (18, bis-(POM)-PMEA) (Hepsera®) 
approved in 2002 for the treatment of HBV infections and the disopropyloxycarbonyloxymethyl 
ester of tenofovir fumarate (19, bis-(POC)-(R)-PMPA fumarate) (Viread®) licensed in 2001 for 
the treatment of HIV infections (Figure 4).  
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Figure 4. Structures of bis-(POM)PMEA (18), bis-(POC)-PMPA fumarate (19), bis-(POM)-
PMCDG (20) and (E)-bis-(POM)TbutP (21). 
In general, bis-POM derivatives are reported to exhibit a 9- to 13-fold greater in vitro 
antiretroviral activity than their corresponding unmodified compounds and show remarkable 
increased bioavailability in vivo. Bis-(POM)-PMEA (18), selected among a series of acyloxy 
methyl ester prodrugs, was first considered as a possible candidate for the treatment of HIV 
infection since it was able to reduce the viral load in plasma.[31] However, the toxicity due to its 
decomposition products (formaldehyde and pivalic acid) generated some concern (Figure 5) [32-
34]. 
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Figure 5. Metabolic pathway for bis-(POM)-PMEA (18). 
In particular the pivalic acid was demonstrated to be responsible for altering carnitine 
homeostasis [35]. Additionally it has been shown that bis-(POM) phosphotriesters were 
chemically unstable and highly susceptible to serum-mediated hydrolysis, factors that limit their 
potential utility for intracellular drug delivery [36]. For these reason, bis-(POM)-PMEA (18) was 
considered too nephrotoxic to permit a long term use at the dosage required inhibition of HIV 
and it was instead approved from FDA only for the treatment HBV. The pivaloyloxymethyl 
prodrugs of (R)-PMPA and (R)-PMP-DAP were also evaluated but due to toxicity concern they 
were not selected for clinical trials.  
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The diisopropyloxycarbonyloxymethyl ester (bis-(POC) is a modification of the bis-(POM)-
ester, offering the advantage to not generate pivalic acid during its bioconversion. The bis-(POC) 
motif was successfully applied to (R)-PMPA (8) leading to bis-(POC)-(R)-PMPA, which was 
selected for clinical trial and subsequently formally approved as its fumarate salt (9) for the 
treatment of HIV. Bis-(POC)-(R)-PMPA fumarate (19) is also currently commercially available 
in combination with emtricitabine (Truvada®) and emtricitabine and efavirenz (Atripla®). 
Subsequently PMCDG dipivoxil (20, bis-(POM)-PMCDG, figure 6) emerged as a possible 
candidate as an oral prodrug for HBV treatment and it is currently in Phase II clinical trials for 
evaluation of efficacy in human [37, 38]. Bis-(POM)-PMCDG is rapidly converted to the parent 
drug in the liver and intestine probably by esterases. The parent drug is further metabolized to a 
nucleotide analogue of guanosine monophosphate, by oxidase such as aldehyde or xanthine 
oxidase. After phosphorylation to di- and tri-phosphate forms, the molecule inhibits viral 
replication following incorporation into viral DNA. 
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Figure 6. Metabolic pathway for bis-(POM)-PMCDG (20). 
More recently bis-POM esters of (S)-HPM-DAP and its cyclic analog were reported by 
Kreþmerová et al. [39]Although these compounds proved to be less active than the 
corresponding alkoxyalkyl ester prodrugs (see next section), they appeared to be less cytotoxic 
and cytostatic. Finally, bis-POM esters of novel ANPs have been described. Among them, (E)-
bis-(POM)TbutP (21) emerged as a potent antiviral agent against several herpes viruses, (HSV-1, 
HSV-2, VZV), representing a new potential antiviral lead for further optimization (Figure 7) 
[40]. 
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Figure 7. Structure for bis-(POM)-(E)-TbutP (21). 
The antiviral potency of CNPs can also be improved considerably by the application of bis-
(POC) prodrug technology. As representative example bis-(POC)-d4TP (22) has been reported to 
improve 29-fold the HIV antiretroviral activity of the corresponding nucleoside (Figure 8) [21]. 
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Figure 8. Structure of bis-(POC)-d4TP (22). 
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Alkoxyalkyl ester prodrugs 
In order to enhance cellular drug uptake of ANPs, the Hostetler group and collaborators have 
developed a series of very promising ether lipid conjugates of ANPs, including (S)-HPMPC (3), 
(S)-HPMPA (1), PME (8), (R)-PMPA (9).[41] Two alkoxyalkyl esters of (S)-HPMPC, 
hexadecyloxypropyl-(S)-HPMPC (23, HDP-(S)-HPMPC) and octadecyloxyethyl-(S)-HPMPC 
(24, ODE-(S)-HPMPC) have been shown to be more active than (S)-HPMPC against HCMV and 
other herpes viruses, exhibiting 2.5- to 4-fold increases in antiviral activity depending on the in 
vitro antiviral assay used (Figure 7).[42] These alkoxyesters were also found to be 25- to 910-
times more active than (S)-HPMPC (3) against variola virus (smallpox) with EC50 values ranging 
from 0.04 to 0.1 PM for HPD-(S)-HPMPC (23) and from 0.01 to 0.03 PM for ODE-(S)-HPMPC 
(24) [43, 44]. Similar results were also reported with monkeypox and cowpox viruses in vitro. 
When tested in vitro against VV, HPD-(S)-HPMPC (23) showed an increase in antiviral activity 
of 58-fold when compared to the parent drug, whereas ODE-(S)-HPMPC (24) was even more 
active with a 231-fold increase (with respect to (S)-HPMPC (3)) and with an EC50 value of 0.2 
PM. An explanation of such increase in antiviral activity of 23 and 24 when compared to (S)-
HPMPC (3) is found from the author in the increased cellular uptake and conversion to (S)-
HPMPC diphosphosphate.  
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Figure 9. Structures of HDP-(S)-HPMPC (23), ODE-(S)-HPMPC (24), HDP-(S)-HMPA (25) 
and ODE-(S)-HMPA (26). 
In vivo these compounds proved as effective as parental (S)-HPMPC (3) in the treatment of 
HCMV infection in a variety of murine models [45]. They also proved to be effective when 
tested in animal model of orthopox diseases such as cowpox, vaccinia and ectromelia virus 
infections [46, 47]. When given orally to mice infected with ectromelia virus by small particle 
aerosol, HDV(S)-HPMPC (23) and ODE(S)-HPMPC (24) were almost full protective by oral 
doses of 5 mg/kg and 10 mg/kg, administered four hours after infection and sustained daily for 
five days. A dose of 10 to 12 mg /kg of respectively HDP-(S)-HPMPC (23) and of ODE-(S)-
HPMPC (24), given orally for five days prior to or few days after nasal infection with cowpox, 
were reported to be able to significantly reduce the mortality. HDP-(S)-HPMPC (23) with the 
name of CMX001 is currently under development by Chimerix, Inc. as an oral drug for treatment 
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of HCMV and small pox infection. Recently CMX001 has completed Phase I clinical trials in 
healthy volunteers and Phase II trials are now in progress in HCMV stem cell transplant patients 
and BK virus infection in kidney transplant patients. However, CMX001 recently failed in an in 
vivo efficacy trial (monkeypox model) likely due to metabolic differences between rodents and 
monkeys [48]. 
Besides (S)-HPMPC derivatives, alkoxyalkyl derivatives of another ANP, (S)-HPMPA (1) 
have been described (Figure 10). Esterification to HDP-(S)-HPMPA (25) or ODE-(S)-HPMPA 
(25) resulted in large increases in antipoxvirus activity raging from 160 to 270-fold versus (S)-
HPMPA (1) [49, 50]. Similar results have observed with CMV infection [51]. Among these 
derivatives, ODE-(S)-HPMPA (26) was the most active compounds in adenovirus infected cells 
with EC50 values of 0.04-0.16 PM compared with 0.19-1.1 of HDP-(S)-HMPA (25). When 
compared to the alkoxyalkyl of (S)-HPMPC (3), the corresponding alkoxyalkyl ester of (S)-
HPMPA (1) displayed similar activities against human and murine CMV.  
 Both (S)-HPMPC (3) and (S)-HPMPA (1) have been reported to inhibit replication of all 
double-stranded DNA viruses and the increased antiviral activity observed after alkoxyalkyl 
HVWHUL¿FDWLRQGRHVQRWDSSHDUWREHVSHFL¿FIRUDSDUWLFXODUW\SHRIvirus. Although (S)-HPMPA 
(1) was reported to be inactive against HIV, HDP-(S)-HPMPA (25) and ODE-(S)-HPMPA (26) 
are described highly active in vitro (with low nanomolar EC50 values), indicating that the alkoxy 
alkylester strategy can eventually wide the range of antiviral activity. The same strategy has been 
applied to PME (8) and (R)-PMPA (9) (Figure 10). HDP-PMEA (27) and HDP-(R)-PMPA (28) 
have been found to be high active against HIV-1. HDP-(R)-PMPA (28) under the name of 
CMX157, is currently in clinical development by Chimerix, Inc. as an oral drug for treatment of 
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HIV infection. Recently it was announced that the first results in human Phase I clinical trials 
demonstrate a favorable safety, tolerability and drug distribution profile for CMX157.  
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Figure 10. Structures of HDP-(S)-PMEA (27) and HDP-(S)-PMPA (28) 
 Other ANPs have been subjected to esterification with alkoxyalkyl groups. In particular the 
antiviral activity of (S)-HPMPC-5aza was reported to be further enhanced by introduction of 
alkoxyalkyl groups, the most active being the hexadecyloxyethyl (HDE) ester derivative (29) with 
EC50 values in the range of 0.003-0.008 Pg/mL for HSV (Figure 11) [52]. 
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Figure 11. Structure of HDE-(S)-cHPMP-azaC (29). 
 
In the case of (S)-HPMP-DAP (5), the ODE derivative has been shown to be a potent 
inhibitor of herpes virus and orthopoxvirus replication. Recently Kreþmerová et al. selected 
HPMP-DAP (5) and its cyclic form for further evaluation, synthesizing a series of different 
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prodrugs and then assessing their in vitro antiviral activity. From these studies the HDP and the 
POM mono ester of (S)-HPMP-DAP and its cyclic analog, emerged as the most active prodrugs 
against VV, HSV, VZV and HCMV. 
The eVWHUL¿FDWLRQ RI ANPs with HDP and ODE chains was designed to increase oral 
bioavailability, based on the resemblance to lysophosphatidylcholine. As a representative 
example for this class of prodrugs, the metabolic pathway of HDP-(S)-HPMPC (23) is reported 
in figure 12. Phospholipase C, which is reported to be the only enzyme responsible for the 
metabolic cleavage, is common in mammalian tissues.  Phospholipase C is not present in plasma 
or pancreatic secretions, providing stability for 23 and other compounds of this type during oral 
absorption and transport in plasma to tissues. 
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Figure 12. Metabolic pathway for HDP-(S)-HPMPC (23). 
Hexaethyleneglycol unit or hydroxylateddecyl- or decyloxyethyl- chains were recently used 
by Krecmerova et al. to mask either PME or (S)-HPMPC [53]. However the antiviral activity of 
these prodrugs was found in general lower or similar to the corresponding parent drug. 
Considering these results the authors conclude that these prodrugs are taken up less efficiently or 
are not suitable substrates for the phospholipase C.  
19 
 
Despite the notable success of the alkoxyalkyl prodrugs developed by Hostetler there are still 
challenges around this this approach because of the potential poor solubility in aqueous 
solutions, arising from a lipid moiety [47, 54]. 
 
Aryl and phenyl ester prodrugs 
Rappresentative examples of these prodrugs are the phenyl (30) and the salicylate ester 
prodrugs (31 and 32) of (S)-cHPMPC (4) reported by Oliyai et al. (Figure 13) [55, 56]. 
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Figure 13. Structures of PhO-(S)-cHPMPC (30), ethylsalicylyl- (31) and butylsalicylyl-(S)-
cHPMPC (32). 
Esterification of (S)-cHPMPC (4) via a phosphoester bond, either with a phenol or a salicylic 
ester produces a new chiral center at the phosphorus, leading to two different diastereoisomers of 
the resulting prodrug (SRp and SSp). The carboxylate function on the salicylate prodrugs provides 
an additional site for chemical modification to tune the lipophilicity, solubility and biological 
reactivity of the prodrug. The compounds were synthesized in a stereospecific manner and 
investigated for their physicochemical and pharmacokinetics properties. The authors 
demonstrated that the chemical stability was dependent on the phosphorus stereochemistry (with 
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the axial isomer more stable than the equatorial) and not greatly with nature of the salicylate 
ester, which on the contrary plays a key role for the enzymatic stability. The axial isomer of 
salicylate prodrugs (I, Figure 14), selected for in vivo oral bioavailability evaluation produces 
(S)-cHPMPC (4) as the major metabolites together with (S)-HPMPC (3) and the mono ester of 
(S)-HPMPC (II) whereas the corresponding equatorial isomer generates only (S)-cHPMPC 
(Figure 12). The results of these studies proved that salicylate ester prodrugs can successfully 
deliver (S)-cHPMPC (4) to the systemic circulation with an oral bioavailability of 4 ranging from 
18.5 (for 31) to 46.3% (for 32).  This prodrug approach presents the advantage to allow oral 
delivery of (S)-cHPMPC (4), while minimizing (S)-HPMPC (3) related toxicity. 
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Figure 14. Metabolic pathway for axial isomers of aryl (S)-cHPMPC prodrugs. 
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A number of esters of PMEA have been synthesized and evaluated for their oral 
bioavailability [57]. Among them, the diphenyl ester was identified as the preferred prodrug 
because it is well absorbed and efficiently converted to the parent compound with an oral 
biovailability of 50% (Figure 15). However, further studies revealed that the diphenyl ester even 
if moderately absorbed is poorly converted to PMEA due to oxidation of the ethyl side chain by 
P450 enzymes to generate the inactive metabolite 2-adenylacetic acid. The same metabolite was 
observed from the activation of bis-(o-ethoxy)phenyl making these two aryl esters unsuitable for 
further evaluation as prodrugs. 
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Figure 15. Structures of bis-(PhO)-PMEA(33) and bis-[(o-EtO)PhO]- PMEA (34). 
Aryl phosphonamidates and phosphonodiamidate prodrugs 
The ProTide (pronucleotide) approach, developed by McGuigan et al. was succesfully 
applied to nucleoside phosphates and then investigated in application to nucleoside 
phosphonates. The ProTide of a nucleoside phosphonate is a phosphonamidate prodrug 
consisting of an amino acid ester promoiety linked via a P-N bond to a nucleoside aryl 
phosphonate. Such a prodrug should be able to facilitate passive diffusion through the cell 
membrane and when it is cleaved, it should deliver the nucleoside phosphonate inside the cell 
releasing non-toxic masking groups. The metabolic activation of the phosphonamidates is 
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generally assumed to follow the same two enzymatic steps involved in the activation of the 
phosphoramidates (Figure 16). The putative mechanism for the activation of the 
phosphonamidates involves an initial carboxylic esterase or carboxypeptidase mediated 
hydrolysis of the carboxylic ester of the amino acid leading to intermediate II. The ester cleavage 
is followed by an internal nucleophilic attack of the acid residue on the phosphorus centre, 
displacing the aryloxy group and giving the transient formation of the putative five-membered 
cyclic intermediate III. This cyclic mixed anhydride is rapidly hydrolyzed to the corresponding 
aminoacyl phosphonamidate ester IV. The ester is then believed to undergo P-N cleavage, 
mediated by a phosphonamidase or may result from simple hydrolysis in more acidic subcellular 
compartment, to eventually release the parent drug V.  
RO C
O
C
R'
H
H
N P
O
CH2
OAr
PHN
O
O
CH2
O
R'
HO P CH2
OH
O
Esterase
-OAr
H2O Phosphonamidase
Nu Nu
Nu
Nu
I II III
IV V
-O C
O
C
R'
H
H
N P
O
CH2
OAr
HO C
O
C
R'
H
H
N P
O
CH2
OH
Nu
 
Figure 16. Metabolic pathway for aryl phosphonamidate prodrugs. 
The ProTide technology was successfully applied by McGuigan and coauthors to PMEA (8) 
and (S)-PMPA (9) [58]. In these studies similar SARs were found for the phosphonamidates of 
PMEA and (S)-PMPA as earlier noted for nucleoside phosphoramidate analogues, with the (L)-
alanine derivatives showing greatly enhanced antiviral potency against HIV compared with the 
parent nucleotide analogue (50 fold increase for phenyloxy methyl-(L)- alaninyl 
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phosphonamidate PMEA prodrug (35) vs PMEA (8) and 50-100 fold increase for phenyloxy 
methyl-(L)- alaninyl phosphonamidate PMPA prodrug (36) vs (S)-PMPA (9) (Figure 17). In 
analogy to this work, Gilead science reported an extensive study on the application of the 
ProTide approach to (S)-PMPA (9) investigating the mechanism of hydrolysis and the 
metabolism of these class of prodrugs [59]. As results of these studies, the phenyloxy isopropyl-
(L)-alaninyl phosphonamidate prodrug of PMPA (37, GS-7340, Figure 17) emerged as a lead 
compound with improved biological properties. In addition, cathepsin A was found to be the 
primary enzyme that activates 37 in human lymphatic tissues [60]. 
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Figure 17. Structures of PMEA phosphonoamidate derivatives 35 and 36 and GS-7340 (37). 
A series of aryl phosphonamidate prodrugs of GS-9148 (16), were also designed by Gilead to 
effectively deliver 16 and its active diphosphorylated metabolite into target cells [61]. The 
phenyloxy ethyl (L)-alaninyl phosphonamidate prodrug (38, GS-9131, Figure 18), improved the 
in vitro antiviral activity of 16 by approximately 50-fold against HIV, demonstrating the most 
favorable esterase (cathepsin) substrate properties in addition to a good in vitro intestinal and 
hepatic stabilities [22, 62]. Following oral dosing (3mg/kg) of 38 in beagle dogs, high levels of 
GS9148 diphosphate were observed inside the cells with a mean oral bioavailability of 26%.19 
All these favorable properties lead to the selection of GS-9131 (38) as a clinical candidate.  
24 
 
O N
N
N
N
NH2
F
OP
OO
HN
GS-9131     38
O
O
 
Figure 18. Structure of phosphonoamidate derivative GS-9131 (38). 
Phosphonodiamidate analogues having two identical amino acids as masking groups of the 
phosphonate moiety trough a P-N bond were designed. They offer two distinct advantages 
compared to phosphonamidate analogues: 1) due to their symmetric structure no phosphorus 
chirality arises; 2) exclusively non toxic promoieties are released. The activation mechanism is 
presumed to be similar to the one previously shown for the cognate phosphonoamidates. As first 
steps the hydrolysis of one amino acid ester lead trough spontaneous cyclization to intermediate 
III, structurally identical to the one derived from the activation of an aryl phosphonamidate (see 
intermediate III in figure 16).  Then exactly the same pathway follows (Figure 19)  
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Figure 19. Metabolic pathway for phosphonodiamidate prodrugs. 
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Several phosphonodiamidate of ANPs containing alkyl (L)-alanine were reported to exhibit 
potent antiviral activities, being bis(butyl-(L)-alaninyl)PME-N6-(cyclopropyl)DAP (39, Figure 
20) the most active of the series against poxviruses [63]. After prodrug cleavage, the 
cPrPMEDAP is intracellularly deaminated by N6-methyl-AMP amino hydrolase to yield the 
potent antiproliferative and antiviral agent PMEG (10).  
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Figure 20. Structures of phosphonodiamidate derivatives of ANPs. 
Recently, the development of a novel and efficient one-pot synthesis of phosphonodiamidates 
directly from the phosphonic acid diesters, VLJQL¿FDQWO\ improved the preparation of this class of 
prodrugs [64]. In this report the methodology has been applied to the synthesis of 40 and 41, 
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which exhibit anti-HIV activity with submicromolar EC50 values and no detectable cytotoxicity 
up to 100 PM, the highest concentration tested. 
Diamidate prodrugs of GS-9148 (16) have been reported. Despite their potent in vitro anti 
HIV activity these diamidates were quite ineffective in delivering 16 into the cells, producing 
after intravenous administration to dogs only approximately 3-fold higher intracellular levels of 
GS-9148 compared to that from the same dose of GS-9148 by itself [61]. 
Cyclosaligenyl ester prodrugs (CycloSal) 
The cyclosaligenyl prodrug strategy was elaborated by Meier and coworkers first to deliver 
monophospates and only later was applied to ANPs. In particular the same group reported the 
synthesis, the stability and the biological evaluation of cycloSal-PMEA prodrugs [65]. The 
structure of the cyclosal PMEA prodrugs present a salicyl alcohol as the only masking unit for 
both the two hydroxyl moieties of the phosphonic acid of PMEA. Due to an unexpected low 
hydrolytic stability of these cycloSal-PMEA prodrugs, the authors had to investigate the more 
stable cycloAmb-PMEA derivatives, in which the salicyl alcohol has been replaced with a 2-
amino benzyl alcohol.  From this study it was proven that the mechanism of activation of 
cycloSal phosphonate is identical to that of the cycloSal-phosphate with the PMEA as the only 
product of hydrolysis (Figure 21). 
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Figure 21. Hydrolysis mechanism for cycloSal- and cycloAmb-PMEA prodrugs. 
Although considerably chemically and enzymatic more stable than cycloSal-PMEA 
prodrugs, cycloAmb-PMEA derivatives surprisingly were reported to exhibit antiviral activity 
somewhat  (2- 3-fold) lower compared to the PMEA and10-fold lower than the cycloSal-PMEA 
prodrugs. The reduced antiviral activity was attributed by the authors to the slow release of 
PMEA from the cycloAmb-PMEA, the rate-limiting step being the cleavage of the intermediate 
benzyl phosphonate ester II. To achieve higher antiviral activity different cycloAmb-PMEA 
derivatives with new substitution patterns were reported. However these new prodrugs failed to 
accelerate the decay of the hydrolysis of the intermediate II, presenting only a slightly improved  
antiviral activity when compared to the previous cyclo-Amb prodrugs [66]. 
S-Acylthioethyl (SATE) esters prodrugs  
On the basis of the favorable results obtained with the S-acylthioethyl (SATE) prodrug for 
delivering monophosphate drugs, the SATE approach was applied successfully to ANPs. In 
28 
 
particular a series of bis-(SATE)-PMEA derivatives were reported. These compounds proved 
enzymatically more stable than the bis-(POM)-PMEA (18)  [67]. Among them the t-bu-SATE 
PMEA (42) emerged as the most promising compound, combining an antiviral potency against 
HIV similar to bis (POM) PMEA with a markedly greater chemical and enzymatic stability. The 
metabolic pathway for bis-(SATE) phosphonate prodrug 42, assumed to be identical to the one 
reported for the phosphate prodrug,[68] is depicted in figure 22. The prodrug, once inside the 
cell, preferentially forms an unstable 2-thioethyl intermediate (I) by the action of a 
carboxyesterase or a reductase and then the 2-thioethyl moiety collapses to episulfide releasing 
the mono SATE nucleotide (II).  Exactly the same sequence of events leads to the release from 
II of the parent drug PMEA (8).  Other report of SATE prodrugs of novel ANPs appeared 
recently indicating that this class of prodrugs may serve to study the in vitro delivery of 
phosphonate drugs [69]. The only concern for this class of prodrugs remains the toxicity which 
may limit their further development On the contrary the SATE approach applied to CNPs did not 
give significant results. To eliminate the potential cell penetration issue associated with the 
anionic phosphonate moiety, several bis-SATE derivatives of adenosine phosphonate analogues 
were prepared [69]. Compared to the parent drugs, characterized by weak anti-HCV activity, the 
anti-HCV activity of the prodrugs is moderately improved, but on the other hand its cytotoxicity 
is drastically increased. 
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Figure 22.  Metabolic pathway for t-bu-bis(SATE) PMEA prodrug (42) 
Peptidomimetic prodrugs  
Very significantly enhanced oral bioavailability of valacyclovir resulting from esterification 
of the hydroxyl group of acyclovir with the carboxylic group of a (L)-valine, has encouraged the 
use of amino acids or dipeptides as promoieties. In this context to increase the oral biovailability 
of acyclic nucleoside phosphonate McKenna and coworkers have proposed an approach in which 
a non-toxic promoiety such as a dipeptide or an amino acid is conjugated to ANPs ((S)-HPMPC 
(3) or (S)-HPMPA (1)) by esterification of the phosphonic acid group with an alcoholic amino 
acid side chain [70]. The other phosphonic OH group was either left free or masked by 
intramolecular esterification affording (S)-cHPMPC or (S)-cHPMPA derivatives or by 
esterification with an ethyl group. In their initial investigation the synthesis and biological 
evaluation of several phosphono dipeptide ester prodrugs of (S)-cHPMPC with a dipeptide 
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attached via the hydroxyl group of a (L)-Serine as well as single amino acid ((L)-Valine, (L)-
Phenyalanine) prodrugs coupled by an ethylene glycol (EG) linkage were reported (Figure 23) 
[71-73]. The dipetide and EG-amino acid conjugates 43 and 44 showed in general an in vitro 
antiviral activity (HCMV) similar to the parent drug. Whereas 43 and 44 did not exhibit 
increased bioavailability compared to the parent compound after direct injection into the 
gastrointestinal tract of rats, interestingly (L)-Val-(L)-Ser-OMe (S)-cHPMPC (45) displayed an 
8-fold increase in oral bioavailability relative to (S)-cHPMPC (4) in an in vivo murine model 
transport studies.  
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Figure 23. Structures of ethylenglycole aminoacid (43 and 44) and serine peptide (S)-
cHPMPC prodrugs (45). 
Since valacyclovir and valganciclovir are actively transported by the peptide-VSHFL¿F
intestinal transporter PEPT1 which is highly expressed in the gastrointestinal tract, McKenna and 
coauthors investigated the possibility that hPEPT1 was involved in the ((L)-Val-(L)-Ser-OMe 
(S)-cHPMPC conjugate (45) observed transport [74]. Under the conditions studied, the authors 
showed that the Val-Ser-OMe dipeptide (S)-cHPMPC stereoisomer conjugates as well as 
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different serine mono amino acid (S)-cHPMPC and (S)-cHPMPA conjugates are recognized, but 
not transported by hPEPT1. According to the author this is probably due to the steric and/or 
polar structural specifics of the linked (S)-cHPMPC drug cargo, suggesting that an alternative 
transport mechanism operates for these prodrugs.  
Despite an enhanced bioavailability, the dipetide (S)-cHPMPC conjugates having the second 
phosphonic OH masked with an ethyl group (46-47), proved to be not suitable as prodrugs due to 
the fact that the ethyl group was not cleaved during in vivo experiments and that the P-OEt 
monoester (S)-HPMPC metabolite did not exhibit significant antiviral activity in an in vitro 
vaccinia plaque reduction assay (Figure 24) [75]. 
Intriguingly, among the serine dipeptide (S)-HPMPC conjugates series, despite the presence 
of an ionizable P±OH group, (L)-Val-(L)-Ser-OiPr (S)-HPMPC (48, Figure 22) displayed the 
greatest oral biovailability with a 15-fold increase in total cidofovir species in the plasma (related 
to 3 and 4) after oral administration. This enhanced oral bioavailability was tentatively justified 
by the authors as the results of a higher chemical and enzymatic stability compared to its cyclic 
analogue [75]. 
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Figure 24. Structures of serine dipeptide (S)-HPMPC prodrugs (46-48). 
More recently, the same authors have reported cyclic (S)-HPMPC and (S)-HPMPA amino 
acid or dipeptide prodrugs in which the phosphonic acid has been masked by esterification with a 
tyrosine hydroxyl group [76].  In this report the authors provided also a convenient method for 
the partial conversion of the prodrug into the more stable Rp diastereomer E\DWUDQVHVWHUL¿FDWLRQ
reaction from the corresponding Sp diastereomer. Along with this new series of peptidomimetic 
prodrugs, (L)-Tyr-NH-iBu (S)-cHPMPA (49, Figure 25) was converted in rat or mouse plasma 
VROHO\ WR WZR DFWLYH PHWDEROLWHV DQG KDG VLJQL¿FDQWO\ HQKDQFHG RUDO ELRDYDLODELOLW\ vs parent 
drug in a mouse model (39% vs <5%). More recently, Kreþmerová and coworkers successfully 
applied the peptidomimetic approach to cyclic (S)-HPMP-DAP (5)[39]. These results suggested 
that these peptidomimetic prodrugs are attractive candidates for further in vivo evaluation. 
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Figure 25. Structure of (L)-Tyr-NHiBu-(S)-cHPMPA (49). 
Independently, a different group described a series of bis-(L)-amino acid ester prodrugs of 
PMEA as potent anti-HBV agents with reduced toxicity [77]. Several of these compounds 
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demonstrated more potent anti-HBV activity and higher selective index (SI) than adefovir 
dipivoxil, which was used in this study as a positive control (Figure 26). 
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Figure 26. Structures of amino acid and peptide PMEA prodrug 50-53. 
Cyclic 1-aryl-1,3-propanyl ester 
The cyclic 1-aryl-1,3-propanyl ester is a new type of prodrug moiety recently reported to 
target phosphate and phosphonate-containing drug to the liver, reducing as consequence their 
systemic exposure [78]. This prodrug class, called HepDirect prodrugs, is selectively activated in 
the liver by the liver specific cytochrome P450 isozyme CYP3A4 (Figure 27). In an effort to 
discover new drugs for treating diseases such as HBV, cyclic 1-aryl-1,3-propanyl ester prodrugs 
of PMEA, were developed. The lead prodrug pradefovir (54, Figure 27) identified among several 
Hept Direct PMEA prodrugs exhibit a high rate of activation in hepatocytes together with good 
oral biovailability in rat and dog species, which was further increased by using the mesylate salt 
to boost water solubility [79]. Evaluation of its individual isomers led to the selection of single 
prodrug isomer (4S, Rp) as the lead compound. Pradefovir is currently under clinical evaluation 
in hepatitis B patients. 
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Discussion 
As a result of extensive efforts in the development of ANPs and CNPs prodrugs, two 
prodrugs of adefovir and tenofovir (Hepsera® and Viread®) and their two formulations 
(Truvada® and Atripla®) in combination with other drugs are on the market (Table 1). 
Table 1 ANPs and CNPs prodrugs on the market for the treatment of antiviral 
infection 
Compounds On the Market 
Adefovir dipivoxil  
bis-(POM)-PMEA 
Hepsera® licensed for the treatment of 
HBV infections.  
Tenofovir disoproxyl fumarate bis-
(POC)-(S)-PMPA fumarate 
Viread® licensed for the treatment of 
HIV infections 
Tenofovir disoproxyl fumarate in Truvada® licensed for the treatment of 
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conbination with emtricitabine. HIV-1 infections 
Tenofovir disoproxyl fumarate in 
combination with emtricitabine and 
efavirenz 
Atripla® licensed for the treatment of 
HIV infections 
However further research is needed in this area. There is still some concern about adefovir 
dipivoxil and tenofovir disopropoxil due to their potential toxicity during long term treatment. 
The same concern can be extended to the clinical candidate PMCDG dipivoxil. Furthermore in 
contrast to PME and PMP series, there is no a commercially available prodrug so far available 
for HPMP-derivatives: cidofovir ((S)-HPMPC, 3), approved with the brand name of Vistide® for 
the treatment of cytomegalovirus retinitis in AIDS patients is applied as an intravenous infusion 
of the free acid. Cidoforir is also accepted as an effective therapy for smallpox infection, caused 
by variola virus, a member of the Orthopoxvirus genus. Although this disease was eradicated 
after an intensive program of vaccination in 1980, there is increasing concern that variola virus 
might be used as a bioterrorist weapon because of its ease of dissemination, contagiousness, and 
high mortality rate. Lack of an oral form of cidofovir significantly limits its usefulness under the 
disruptive conditions of a large-scale biowarfare attack. 
A considerable number of ANP and CNP prodrugs have been evaluated, but only a few of 
them passed the preclinical studies and are now in clinical trials (Table 2). This likely arises from 
the complexity in designing prodrugs appropriate for clinical use in terms of stability, 
metabolism, toxicology and side effects. Some of them appear promising, such as the long chain 
alkyl ester prodrugs developed by Hostetler and applied to different ANPs or the 
phosphonamidate of ¶-F-d4AP. However, they may suffer of potential drawn back such as lack 
of solubility for the long chain prodrugs or possible toxicity due to the releasing of the phenol in 
36 
 
the case of the phosphonoamidate prodrug for which additional diastereoisomer issue need also 
to be taken in account.  
In these scenario other prodrugs strategies like the phosphono-diamidate and the 
peptimomimetic conjugates prodrugs are thus of extremely importance and may offer valuable 
alternative to those prodrugs already in clinical trials. Hep-direct prodrugs appear instead the 
obvious option when targeting the liver is required.  
Table 2 ANPs and CNPs prodrugs in clinical trials for treatment of antiviral 
infections 
Compounds In clinical trials 
Hexadecyloxypropyl-(S)-HPMPC 
HDP-(S)-HPMPC (23) 
CMX001 is under clinical development by 
Chimerix, Inc. as an oral drug for the 
treatment of HCMV and small pox 
infections. Currently in Phase II trials 
Hexadecyloxypropyl-(R)-PMPA 
HDP-(R)-PMPA (28)  
CMX157 is under clinical development by 
Chimerix, Inc. as an oral drug for the 
treatment of HIV infections. Currently in 
Phase I trials. 
PMCDG dipivoxil 
bis-(POM)-PMCDG (20) 
 
LB80380 is under clinical development by 
LG Life Sciences as an oral drug for the 
treatment of chronic HBV infection and of 
lamivudine-resistant disease. Currently in 
Phase II clinical trials 
Phenyloxy-ethyl-(L)-alaninyl 
phosphonamidate ¶)-d4AP  
GS-9131 (38) 
Preclinical studies for the treatment of HIV 
infections. 
Pradefovir (59) MB06866 is under clinical development by 
Valeant Pharmaceuticals International, Inc. 
and Schering-Plough Corporation as an 
oral drug for chronic HBV infection.  
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In summary a variety of ANP and CNP prodrugs with diverse chemical structures are 
presented in this review. Although extensive efforts have been made in developing these 
prodrugs for the management of antiviral infection there are still exciting future prospects for 
either novel ANPs and CNPs and/or their prodrugs. 
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